Purchase Order 75F40124P00440
Award Date
9/4/24
Potential Completion Date
9/29/25
Potential Value
$99K
Federal Agency
Food and Drug Administration
Awardee
Olink Proteomics Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Waltham, MA 02453, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $106,675.00 firm fixed-price purchase order contract to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company, for a proteomic analysis of cancer patient plasma samples. The contract, which has no set-aside designation, will be performed at Olink's facility in Waltham, Massachusetts and involves the comprehensive analysis of over 5,000 proteins across 100 plasma samples using Olink's advanced multiplex immunoassay...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a firm-fixed price purchase order contract to Olink Proteomics Inc. for $115,920.00 to provide protein biomarker analysis of cardiotoxicity in human plasma samples. The contract has a completion date of December 31, 2022 and was awarded on June 9, 2022. No set-aside designation was used for this award. Olink Proteomics is a biotechnology company that specializes in proteomics solutions and has held...
This is a $79,345.00 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company. The contract is for quantitative proteomics measurement of human COVID-19 plasma samples, which supports the FDA's research efforts related to the COVID-19 pandemic. Olink Proteomics specializes in protein biomarker discovery and has provided a range of proteomics instruments, reagents, and analysis services to various...
This firm fixed price purchase order contract was awarded by the Food and Drug Administration (FDA) to Olink Proteomics AB, a foreign-owned for-profit manufacturer based in Sweden. The $75,718 contract is for the provision of proteomics analysis services, including the analysis of plasma samples to support biomedical research across disease areas such as cancer, cardiovascular disease, infectious disease, and COVID-19. Olink has previously provided similar services to federal agencies like the...
This is a $147,501.31 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company. The contract, which has no set-aside designation, is for the acquisition of Olink's O-Link System and reagents. Olink Proteomics specializes in protein biomarker discovery solutions and has provided a variety of proteomics instruments, assay kits, and analysis services to support government research efforts,...
This federal contract award, valued at $24,775.29, was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company located in Waltham, Massachusetts. The contract requires Olink to provide proteomic kits to isolate and quantify proteins in plasma and bronchiole alveolar lavage samples. This is a firm fixed-price purchase order contract with a completion...
The Department of Health and Human Services Food and Drug Administration awarded a $87,620 purchase order to Olink Proteomics Inc. of Waltham, Massachusetts. The firm fixed price contract is for quantitative proteomics measurement of 100 human COVID-19 plasma samples. Performance will take place in Waltham from July 18, 2023 through December 8, 2023. The solicitation sought quantitative proteomics measurement of the specified plasma samples, as described in the attached combined synopsis and...
This firm fixed-price purchase order was awarded by the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Olink Proteomics AB, a foreign-owned for-profit organization, to provide Olink Biomarker Analysis Services. The $249,250.00 contract has a performance period through May 16, 2024 and does not have a set-aside designation. Olink Proteomics specializes in multiplex protein biomarker analysis platforms and has previously supported NIH, Food and Drug...
This contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Olink Proteomics AB, a foreign-owned for-profit organization, to provide testing services using inflammation and cardiometabolic panels. The contract has a period of performance from May 1, 2018 to April 30, 2019 and a firm fixed price contract value of $157,489.90. No set-aside designation was indicated. Olink Proteomics AB has provided similar proteomics analysis...
This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), to Olink Proteomics Inc., a foreign-owned for-profit biotechnology company. The contract, valued at $24,424.80, is for Olink to provide proteomics assays to support an NHLBI research project investigating the link between plasma myokine abundance and physical capacity in patients with non-tuberculous mycobacterial...